IMU Stock Overview
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.20|
|52 Week High||AU$0.63|
|52 Week Low||AU$0.15|
|1 Month Change||-13.33%|
|3 Month Change||-11.36%|
|1 Year Change||-58.51%|
|3 Year Change||1,047.06%|
|5 Year Change||1,400.23%|
|Change since IPO||100.00%|
Recent News & Updates
|IMU||AU Biotechs||AU Market|
Return vs Industry: IMU underperformed the Australian Biotechs industry which returned -8% over the past year.
Return vs Market: IMU underperformed the Australian Market which returned -0% over the past year.
|IMU Average Weekly Movement||13.4%|
|Biotechs Industry Average Movement||9.9%|
|Market Average Movement||9.3%|
|10% most volatile stocks in AU Market||16.3%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: IMU is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: IMU's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in Phase 1b/2 study for gastric cancer.
Imugene Fundamentals Summary
|IMU fundamental statistics|
Is IMU overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IMU income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0046|
|Net Profit Margin||-320.60%|
How did IMU perform over the long term?See historical performance and comparison
How is Imugene forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMU's revenue (20.2% per year) is forecast to grow faster than the Australian market (4.8% per year).
High Growth Revenue: IMU's revenue (20.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMU is forecast to be unprofitable in 3 years.
How has Imugene performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMU is currently unprofitable.
Growing Profit Margin: IMU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMU is unprofitable, and losses have increased over the past 5 years at a rate of 44.6% per year.
Accelerating Growth: Unable to compare IMU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.7%).
Return on Equity
High ROE: IMU has a negative Return on Equity (-17.95%), as it is currently unprofitable.
How is Imugene's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IMU's short term assets (A$125.3M) exceed its short term liabilities (A$6.7M).
Long Term Liabilities: IMU's short term assets (A$125.3M) exceed its long term liabilities (A$1.1M).
Debt to Equity History and Analysis
Debt Level: IMU is debt free.
Reducing Debt: IMU has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMU has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IMU has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 37.9% each year
What is Imugene current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMU's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IMU has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Leslie Chong serves as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21, 2016. Ms. Chon...
CEO Compensation Analysis
Compensation vs Market: Leslie's total compensation ($USD557.96K) is below average for companies of similar size in the Australian market ($USD1.03M).
Compensation vs Earnings: Leslie's compensation has increased whilst the company is unprofitable.
Experienced Management: IMU's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Experienced Board: IMU's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.9%.
Imugene Limited's employee growth, exchange listings and data sources
- Name: Imugene Limited
- Ticker: IMU
- Exchange: ASX
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$1.199b
- Shares outstanding: 5.85b
- Website: https://www.imugene.com
- Imugene Limited
- 37 Bligh Street
- SUITE 804
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.